A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) C07H 21/04 (2006.01) C07K 14/34 (2006.01) C12N 5/00 (2006.01) C12N 15/63 (2006.01) C12N 15/85 (2006.01) C12N 15/86 (2006.01) C12N 15/88 (2006.01)
Patent
CA 2389690
The present invention relates to pharmaceutical compositions capable of specifically inducing cell death in the proliferating angiogenic endothelial cells associated with solid tumors and other angiogenesis associated diseases. More specifically, the present invention relates to nucleotide constructs that are selectively active in angiogenic endothelial cells and that encode highly toxic agents, such as diphtheria toxin, for expression in such cells.
La présente invention concerne des compositions pharmaceutiques qui peuvent spécifiquement induire la mort cellulaire dans des cellules endothéliales angiogéniques proliférantes associées à des tumeurs solides et à d'autres maladies associées à l'angiogenèse. La présente invention concerne plus particulièrement des constructions nucléotidiques qui sont actives de façon sélective dans les cellules endothéliales angiogéniques et qui codent des agents hautement toxiques, tels que des toxines diphtériques, de façon à exprimer ces agents dans ces cellules.
Kaletta Cortina
Maxwell Francoise
Maxwell Ian H.
Naujoks Kurt W.
Gowling Lafleur Henderson Llp
Mbt Munich Biotechnology Gmbh
Munich Biotech Ag
The Regents Of The University Of Colorado
University Technology Corporation
LandOfFree
Selective toxin expression in angiogenic endothelial cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective toxin expression in angiogenic endothelial cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective toxin expression in angiogenic endothelial cells will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1648934